S&P 500   3,798.91
DOW   30,930.52
QQQ   316.96
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.96
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.96
S&P 500   3,798.91
DOW   30,930.52
QQQ   316.96
Log in
LON:INS

Instem plc (INS.L) Share Forecast, Price & News

GBX 502
-3.00 (-0.59 %)
(As of 01/19/2021 01:42 PM ET)
Add
Compare
Today's Range
490
Now: GBX 502
505
50-Day Range
430
MA: GBX 480.59
510
52-Week Range
340
Now: GBX 502
558
Volume28,313 shs
Average Volume64,471 shs
Market Capitalization£102.82 million
P/E Ratio251.00
Dividend YieldN/A
BetaN/A
Instem plc, together with its subsidiaries, provides information technology applications to the life sciences healthcare market worldwide. The company offers solutions for data collection, management, and analysis to meet the needs of life science and healthcare organizations for data-driven decision making. Its solutions include ALPHADAS, an eSource EDC system for early phase clinical trials; Ames Study Manager, an integrated suite of software for conducting the Bacterial Reverse Mutation Test; Toxicology Resource Planning, a toxicology solution; Comet Assay IV, a live video imaging system for reproducible comet slide scoring; Cyto Study Manager, a data acquisition and reporting solution; lead scope for computational toxicology; Logbook, a repository for information; NOTOCORD-hem software platforms to acquire, display, and analyze physiological signals; and Provantis, a Windows-based system for organizations and universities that are engaged in non-clinical evaluation studies. The company also provides Samarind RMS to manage medical product information; Sorcerer Colony Counter for automatic plate counter; SEND Explorer, a web-based application with optional data warehousing capabilities; submit platform that provides a suite of integrated tools and services for the creation and management of SEND datasets and associated documents for contract research organizations and sponsors; and SENDTrial, a full Web based solution that can be accessed through a subscription. In addition, it offers data management, cloud, safety assessment, regulatory information management, solution deployment, and validation services. Further, the company provides software solutions for extracting intelligence from research and development related healthcare data; and develops, manufactures, and supplies software and hardware products for in vitro study data collection and study management. Instem plc was founded in 1969 and is headquartered in Stone, the United Kingdom.
Instem plc (INS.L) logo

MarketRank

Overall MarketRank

0.36 out of 5 stars

Analyst Opinion: 0.0Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Healthcare Information Services
Sub-IndustryN/A
CUSIPN/A
CIKN/A
Phone+44-1785-825600
Employees268

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£28.10 million
Cash FlowGBX 46.47 per share
Book ValueGBX 81.20 per share

Profitability

Miscellaneous

Market Cap£102.82 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 502
-3.00 (-0.59 %)
(As of 01/19/2021 01:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INS News and Ratings via Email

Sign-up to receive the latest news and ratings for INS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Instem plc (INS.L) (LON:INS) Frequently Asked Questions

How has Instem plc (INS.L)'s stock been impacted by COVID-19 (Coronavirus)?

Instem plc (INS.L)'s stock was trading at GBX 500 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, INS shares have increased by 0.4% and is now trading at GBX 502.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Instem plc (INS.L)?

Wall Street analysts have given Instem plc (INS.L) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Instem plc (INS.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Instem plc (INS.L)'s key competitors?

What other stocks do shareholders of Instem plc (INS.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Instem plc (INS.L) investors own include Abeona Therapeutics (ABEO), ARCA biopharma (ABIO), Apollo Investment (AINV), Alico (ALCO), Corindus Vascular Robotics (CVRS), Delta Apparel (DLA), Document Security Systems (DSS), Evans Bancorp (EVBN), The LGL Group (LGL) and UQM Technologies (UQM).

Who are Instem plc (INS.L)'s key executives?

Instem plc (INS.L)'s management team includes the following people:
  • Mr. Phil J. Reason, CEO & Exec. Director (Age 58, Pay $261k)
  • Mr. Nigel John Goldsmith, CFO, Sec. & Exec. Director (Age 58, Pay $141k)
  • Ms. Marybeth Thompson, Chief Operating Officer
  • Dr. Gordon Smith Baxter, Chief Scientific Officer
  • Mr. Gary Mitchell, VP of Global Marketing
  • Mr. Jerry Hacker, Sr. VP of Global Sales
  • Mr. Adrian Gare, VP of Corp. Devel.
  • Ms. Eve Leconte, Head of People Services
  • Mr. Mike Harwood, Exec. VP of Regulatory eStudy Solutions
  • Mr. Gregor Grant, Exec. VP of Preclinical Solutions

What is Instem plc (INS.L)'s stock symbol?

Instem plc (INS.L) trades on the London Stock Exchange (LON) under the ticker symbol "INS."

How do I buy shares of Instem plc (INS.L)?

Shares of INS and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Instem plc (INS.L)'s stock price today?

One share of INS stock can currently be purchased for approximately GBX 502.

How big of a company is Instem plc (INS.L)?

Instem plc (INS.L) has a market capitalization of £102.82 million and generates £28.10 million in revenue each year. Instem plc (INS.L) employs 268 workers across the globe.

What is Instem plc (INS.L)'s official website?

The official website for Instem plc (INS.L) is www.instem.com.

How can I contact Instem plc (INS.L)?

Instem plc (INS.L)'s mailing address is Diamond Way, Stone Business Park, STONE, ST15 0SD, United Kingdom. The company can be reached via phone at +44-1785-825600.

This page was last updated on 1/19/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.